Stevanato Group S.p.a. (STVN)

$19.6

-0.19

(-0.96%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $19.47
    $20.44
    $19.60
    downward going graph

    0.66%

    Downside

    Day's Volatility :4.75%

    Upside

    4.11%

    downward going graph
  • $16.56
    $36.20
    $19.60
    downward going graph

    15.51%

    Downside

    52 Weeks Volatility :54.25%

    Upside

    45.86%

    downward going graph

Returns

PeriodStevanato Group S.p.a.Sector (Health Care)Index (Russel 2000)
3 Months
-28.14%
6.5%
0.0%
6 Months
-37.61%
7.1%
0.0%
1 Year
-38.75%
9.8%
0.0%
3 Years
-1.05%
14.2%
-20.2%

Highlights

Market Capitalization
5.9B
Book Value
$4.88
Dividend Share
0.053
Dividend Yield
0.27%
Earnings Per Share (EPS)
0.56
PE Ratio
38.43
PEG Ratio
3.57
Wall Street Target Price
28.07
Profit Margin
12.57%
Operating Margin TTM
12.21%
Return On Assets TTM
5.88%
Return On Equity TTM
11.54%
Revenue TTM
1.1B
Revenue Per Share TTM
4.08
Quarterly Revenue Growth YOY
-0.8%
Gross Profit TTM
319.8M
EBITDA
257.5M
Diluted Eps TTM
0.56
Quarterly Earnings Growth YOY
-0.34
EPS Estimate Current Year
0.56
EPS Estimate Next Year
0.68
EPS Estimate Current Quarter
0.12
EPS Estimate Next Quarter
0.15

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Stevanato Group S.p.a.(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
11
11
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 43.21%

Current $19.60
Target $28.07

Company Financials

FY19Y/Y Change
Revenue
601.0M
-
Net Income
43.9M
-
Net Profit Margin
7.31%
-
FY20Y/Y Change
Revenue
814.3M
↑ 23.39%
Net Income
96.6M
↑ 100.28%
Net Profit Margin
11.86%
↑ 4.55%
FY21Y/Y Change
Revenue
955.7M
↑ 27.47%
Net Income
152.1M
↑ 71.08%
Net Profit Margin
15.92%
↑ 4.06%
FY22Y/Y Change
Revenue
1.1B
↑ 16.57%
Net Income
153.0M
↑ 6.35%
Net Profit Margin
14.52%
↓ 1.4%
FY23Y/Y Change
Revenue
1.1B
↑ 8.07%
Net Income
145.6M
↑ 1.95%
Net Profit Margin
13.7%
↓ 0.82%
Q4 FY22Q/Q Change
Revenue
312.9M
↑ 19.1%
Net Income
51.8M
↑ 33.59%
Net Profit Margin
16.56%
↑ 1.79%
Q1 FY23Q/Q Change
Revenue
259.5M
↓ 18.52%
Net Income
30.8M
↓ 41.58%
Net Profit Margin
11.88%
↓ 4.68%
Q2 FY23Q/Q Change
Revenue
278.6M
↑ 7.27%
Net Income
37.4M
↑ 21.14%
Net Profit Margin
13.41%
↑ 1.53%
Q3 FY23Q/Q Change
Revenue
271.4M
↑ 6.31%
Net Income
37.9M
↑ 10.67%
Net Profit Margin
13.96%
↑ 0.55%
Q4 FY23Q/Q Change
Revenue
312.4M
↑ 15.11%
Net Income
45.2M
↑ 19.36%
Net Profit Margin
14.48%
↑ 0.52%
Q1 FY24Q/Q Change
Revenue
256.3M
↓ 24.02%
Net Income
20.3M
↓ 58.4%
Net Profit Margin
7.93%
↓ 6.55%
FY18Y/Y Change
Total Assets
894.2M
-
Total Liabilities
629.4M
-
FY19Y/Y Change
Total Assets
988.2M
↑ 12.87%
Total Liabilities
690.9M
↑ 12.1%
FY20Y/Y Change
Total Assets
1.2B
↑ 9.73%
Total Liabilities
809.2M
↑ 6.66%
FY21Y/Y Change
Total Assets
1.6B
↑ 46.54%
Total Liabilities
653.7M
↓ 12.26%
FY22Y/Y Change
Total Assets
1.8B
↑ 16.99%
Total Liabilities
711.1M
↑ 15.0%
FY23Y/Y Change
Total Assets
2.1B
↑ 24.94%
Total Liabilities
939.7M
↑ 41.57%
Q4 FY22Q/Q Change
Total Assets
1.8B
↑ 1.92%
Total Liabilities
711.1M
↓ 0.2%
Q1 FY23Q/Q Change
Total Assets
1.9B
↑ 5.04%
Total Liabilities
777.1M
↑ 7.36%
Q2 FY23Q/Q Change
Total Assets
2.0B
↑ 3.76%
Total Liabilities
437.0M
↓ 43.8%
Q3 FY23Q/Q Change
Total Assets
1.9B
↑ 6.54%
Total Liabilities
377.3M
↓ 5.79%
Q4 FY23Q/Q Change
Total Assets
2.1B
↑ 7.59%
Total Liabilities
939.7M
↑ 149.06%
Q1 FY24Q/Q Change
Total Assets
2.4B
↑ 6.83%
Total Liabilities
953.5M
↓ 6.02%
FY19Y/Y Change
Operating Cash Flow
47.7M
-
Investing Cash Flow
-83.3M
-
Financing Cash Flow
47.2M
-
FY20Y/Y Change
Operating Cash Flow
191.5M
↑ 265.63%
Investing Cash Flow
-118.2M
↑ 29.26%
Financing Cash Flow
-32.6M
↓ 162.88%
FY21Y/Y Change
Operating Cash Flow
151.0M
↓ 14.36%
Investing Cash Flow
-109.2M
↑ 0.35%
Financing Cash Flow
288.6M
↓ 1060.89%
FY22Y/Y Change
Operating Cash Flow
110.7M
↓ 22.51%
Investing Cash Flow
-260.3M
↑ 151.95%
Financing Cash Flow
-47.7M
↓ 117.46%
Q4 FY22Q/Q Change
Operating Cash Flow
64.0M
↓ 1676.45%
Investing Cash Flow
-73.7M
↑ 59.28%
Financing Cash Flow
-19.9M
↑ 87.73%
Q1 FY23Q/Q Change
Operating Cash Flow
40.5M
↓ 37.8%
Investing Cash Flow
-104.6M
↑ 39.35%
Financing Cash Flow
24.0M
↓ 218.28%
Q2 FY23Q/Q Change
Operating Cash Flow
26.6M
↓ 34.29%
Investing Cash Flow
-104.6M
↑ 0.0%
Financing Cash Flow
-27.7M
↓ 215.45%
Q3 FY23Q/Q Change
Operating Cash Flow
33.5M
↑ 37.3%
Investing Cash Flow
-132.2M
↑ 37.85%
Financing Cash Flow
101.7M
↓ 500.39%

Technicals Summary

Sell

Neutral

Buy

Stevanato Group S.p.a. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Stevanato Group S.p.a.
Stevanato Group S.p.a.
15.33%
-37.61%
-38.75%
-1.05%
0.61%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-1.32%
16.54%
32.6%
35.62%
148.32%
Resmed Inc.
Resmed Inc.
11.69%
9.57%
-6.0%
-19.79%
64.22%
Becton, Dickinson And Company
Becton, Dickinson And Company
0.5%
-1.64%
-17.69%
-6.68%
-8.49%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-14.37%
-23.3%
-26.95%
-26.58%
102.44%
Alcon Ag
Alcon Ag
2.41%
20.84%
8.21%
30.7%
54.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Stevanato Group S.p.a.
Stevanato Group S.p.a.
38.43
38.43
3.57
0.56
0.12
0.06
0.0
4.88
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
78.14
78.14
7.13
6.63
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
32.24
32.24
1.75
7.73
0.22
0.12
0.01
31.52
Becton, Dickinson And Company
Becton, Dickinson And Company
50.71
50.71
1.34
13.04
0.05
0.03
0.02
88.74
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
42.71
42.71
6.72
7.74
0.21
0.11
0.0
36.72
Alcon Ag
Alcon Ag
44.05
44.05
4.59
3.07
0.05
0.02
0.0
42.13
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Stevanato Group S.p.a.
Stevanato Group S.p.a.
Buy
$5.9B
0.61%
38.43
12.57%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$161.3B
148.32%
78.14
27.65%
Resmed Inc.
Resmed Inc.
Buy
$30.8B
64.22%
32.24
20.91%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$68.6B
-8.49%
50.71
6.76%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$23.7B
102.44%
42.71
19.42%
Alcon Ag
Alcon Ag
Buy
$45.8B
54.72%
44.05
10.96%

Insights on Stevanato Group S.p.a.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 312.41M → 237.38M (in $), with an average decrease of 24.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 45.23M → 18.81M (in $), with an average decrease of 58.4% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 32.6% return, outperforming this stock by 71.3%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 35.6% return, outperforming this stock by 36.7%

Institutional Holdings

  • Conestoga Capital Advisors, LLC

    2.49%

  • Neuberger Berman Group LLC

    1.61%

  • Copeland Capital Management, LLC

    0.88%

  • Lazard Asset Management LLC

    0.83%

  • Wellington Management Company LLP

    0.81%

  • Sands Capital Management, LLC

    0.68%

Corporate Announcements

  • Stevanato Group S.p.a. Dividends September,2024

    In the quarter ending September,2024. Stevanato Group S.p.a. has declared dividend of $0.05

    Read More

Company Information

founded in 1949, stevanato group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. it is comprised of two operational divisions: - pharmaceutical systems (ompi and balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. - engineering systems (spami, optrel, innoscan and svm brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. these two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that stevanato group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. the group also benefits from the sglab activ

Organization
Stevanato Group S.p.a.
Employees
5635
CEO
Mr. Franco Stevanato
Industry
Basic Materials

Discover More

FAQs